Bf-002S Sheep Anti-Rat Fx1A Serum

Description

Establishing a Passive Heymann Nephritis model requires an anti-Fx1A serum that matches the target animal, experimental design and intended level of disease severity. biofargo Bf-002S is a Sheep Anti-Rat Fx1A Serum supplied for the induction of Passive Heymann Nephritis in rats.

The product is supplied as 25 mL of Anti-Fx1A Serum in 0.02 M phosphate-buffered saline at pH 7.3. One package contains sufficient antibody for 25 rats weighing 175-200 g when used according to the stated directions. Male Sprague-Dawley rats are recommended, while other rat strains have not been tested.

Passive Heymann Nephritis production is dose-dependent. The complete antibody dose must be delivered, and differences between antiserum lots, rat sources and experimental requirements can affect the resulting disease severity. A dose-response study is therefore recommended for each lot before establishing the final experimental conditions.

The product data describe an initial heterologous phase followed by an autologous phase. Sheep IgG and rat C3 can localize in the glomerular capillaries, proteinuria can develop, and subepithelial immune deposits can be observed. The product has not been validated in mice, and chronic disease has not been verified using this Anti-Fx1A Serum.

Specification

Features

• Defined model application: Supplied for the induction of Passive Heymann Nephritis in rats.
• Species-specific product: Sheep antiserum directed against rat Fx1A.
• 25 mL package: Contains sufficient antibody for 25 rats weighing 175-200 g when used according to the stated directions.
• Specified formulation: Supplied in 0.02 M phosphate-buffered saline at pH 7.3.
• Frozen storage: Store at -20°C or below and avoid repeated freeze-thaw cycles.
• Pre-use preparation: Centrifuge the Anti-Fx1A Serum at 3,000 rpm before use.
• Recommended animals: Male Sprague-Dawley rats are recommended.
• Dose-dependent response: Complete delivery of the antibody dose is important for disease production.
• Lot-specific study design: A dose-response study is recommended to establish the desired disease severity for each antiserum lot.

Application

biofargo Bf-002S Sheep Anti-Rat Fx1A Serum is supplied for the induction of Passive Heymann Nephritis in rats.

• Passive Heymann Nephritis induction
• Anti-Fx1A rat model establishment
• Proteinuria assessment in the Passive Heymann Nephritis model
• Glomerular sheep IgG deposition assessment
• Glomerular rat C3 localization assessment
• Subepithelial immune-deposit assessment
• Glomerular basement membrane change assessment
• Mesangial matrix change assessment

Heterologous Disease Phase

Faint to moderate deposits of heterologous sheep IgG can become detectable in the glomerular capillaries by immunofluorescence within minutes after a single administration of Anti-Fx1A Serum. The intensity and granularity of these deposits can increase during the following 3-5 days. Rat C3 can also localize in a granular pattern, and proteinuria can develop after approximately 5 days.

Autologous Disease Phase

The autologous phase can become noticeable 7-10 days after administration of the Anti-Fx1A antibody. The product data describe increased proteinuria and glomerular localization of rat IgG in a string-of-pearls pattern by immunohistochemistry. Subepithelial immune deposits can be observed by electron microscopy.

By approximately 3 weeks, proteinuria can reach 100-200 mg per 24 hours when measured using the Bradford assay. During the first few weeks, glomeruli may appear unremarkable by routine light microscopy. The data sheet describes possible progression to thickened basement membranes, increased mesangial matrix and possible sclerosis after approximately 3 months. Chronic disease, however, has not been verified using this Anti-Fx1A Serum.

FAQ